Logo image
Back
A case‐matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma
Journal article   Open access   Peer reviewed

A case‐matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma

Lynn D. Kowalski, Anisa I. Kanbour, Fredric V. Price, Sydney D. Finkelstein, Wayne A. Christopherson, Jan C. Seski, Gregory J. Naus, Judith A. Burnham, Amal Kanbour‐Shakir and Robert P. Edwards
Cancer, v 79(8), pp 1587-1594
15 Apr 1997
DOI: https://doi.org/10.1002/(SICI)1097-0142(19970415)79:8<1587::AID-CNCR22>3.0.CO;2-T
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1002/(sici)1097-0142(19970415)79:8<1587::aid-cncr22>3.0.co;2-tView
Published, Version of Record (VoR)Maybe Open Access (Publisher Bronze),  Open

Abstract

aneuploidy c‐erb B‐2 protooncogene protein flow cytometry immunohistochemistry ovarian neoplasms Ovary p53 protein peritoneal neoplasms
BACKGROUND Extraovarian müllerian adenocarcinoma (EOM) resembles primary ovarian carcinoma (POC) both histologically and clinically, yet little is known regarding the molecular genetic characteristics of this entity. The objective of this study was to compare the expression of three molecular markers of tumor behavior in EOMs and POCs. METHODS Forty‐four patients meeting strict criteria for EOM were identified and matched to POC controls for age, stage, tumor histology and grade, cytoreductive surgery, and survival. Immunohistochemistry was used to determine overexpression of p53 and HER‐2/neu. DNA content was evaluated by flow cytometry. Direct DNA sequencing of exons 5‐8 of the p53 gene was performed in nine EOM tumors. Statistical comparisons were made using chi‐square, Kaplan‐Meier, and Mantel‐Cox log rank methods. RESULTS Overexpression of HER‐2/neu was demonstrated in 59% (26 of 44) of the EOM group versus 36% overexpression (16 of 44) in the POC controls (P = 0.05). Overexpression of p53 was noted in 48% of the EOM cases, similar to the 59% incidence observed in the control group (P = 0.29). Missense mutations were found in 9 of 9 EOM tumors showing strong p53 nuclear immunostaining. No significant difference in the incidence of aneuploidy was observed when EOM cases were compared with POC controls (65% vs. 63%). High tumor grade was strongly associated with HER‐2/neu overexpression in the EOM group (P = 0.002). None of the parameters studied were predictive of prognosis within the EOM and POC groups. CONCLUSIONS Although overexpression of p53 protein, p53 gene mutations, and abnormal DNA content were similar between EOMs and POCs, EOMs demonstrated almost twice the rate of HER‐2/neu overexpression. This result suggests that distinct genetic events may be responsible for malignant transformation in EOMs versus POCs. Cancer 1997; 79:1587‐94. © 1997 American Cancer Society. Extraovarian müllerian adenocarcinomas display twice the frequency of HER‐2/neu overexpression as primary ovarian carcinomas.

Metrics

10 Record Views
50 citations in Web of Science
43 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#5 Gender Equality
#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Oncology
Logo image